| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Paliperidone (Invega; Invega Sustenna; Invega Sustenna; 9-hydroxyrisperidone), the main active metabolite of Risperidone, is a potent serotonin-2A and dopamine-2 receptor antagonist used for the treatment of schizophrenia. Paliperidone works in a concentration-dependent manner by significantly increasing the intracellular accumulation of Rh123 and DOX. Paliperidone has outperformed other APDs in a number of oxidative stress-scavenging metrics, including produced glutathione in bulk, low HNE, and protein carbonyl production.
| Targets |
α2 adrenergic receptor; α1 adrenergic receptor; α adrenergic receptor; 5-HT2A Receptor; D2 Receptor
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C23H27FN4O3
|
|
|---|---|---|
| Molecular Weight |
426.48
|
|
| Exact Mass |
426.21
|
|
| Elemental Analysis |
C, 64.77; H, 6.38; F, 4.45; N, 13.14; O, 11.25
|
|
| CAS # |
144598-75-4
|
|
| Related CAS # |
Paliperidone-d4; 1020719-55-4
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
|
|
| InChi Key |
PMXMIIMHBWHSKN-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
|
|
| Chemical Name |
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3448 mL | 11.7239 mL | 23.4478 mL | |
| 5 mM | 0.4690 mL | 2.3448 mL | 4.6896 mL | |
| 10 mM | 0.2345 mL | 1.1724 mL | 2.3448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04940039 | Active Recruiting |
Drug: Risperidone 3 mg Drug: Paliperidone Palmitate 50 mg eq. |
Schizophrenia | Janssen-Cilag International NV | July 22, 2021 | Phase 4 |
| NCT03485417 | Recruiting | Drug: Paliperidone Drug: Aripiprazole |
Stimulant Abuse Pharmacotherapy |
The University of Hong Kong | June 1, 2019 | Phase 2 Phase 3 |
| NCT06060886 | Not yet recruiting | Drug: Aripiprazole Drug: Paliperidone |
Schizophrenia Diabetes |
Consorcio Centro de Investigación Biomédica en Red (CIBER) |
November 1, 2023 | Phase 4 |
| NCT01399450 | Completed | Drug: paliperidone | Schizophrenia | Seoul National University Hospital |
August 2011 | Phase 4 |
| NCT00761605 | Completed | Drug: Paliperidone | Schizophrenia | Janssen Korea, Ltd., Korea | April 2008 | Phase 4 |
 |
|---|
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA